ArticleCell reports. Medicine2023
Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 50 citations in OpenAlex.
- From data to discovery: a unified framework for human immunology.Nature immunology · 2026Article
- Virus reactivation in acute and long COVID-19.Nature · 2026Article
- Omics Approaches in Hantavirus Research: Current Advances, Challenges, and Future Perspectives.Biotech (Basel (Switzerland)) · 2026Review
- Ocular community state types reveal distinct microbial compositions among microbiomes with implications for trachoma control.bioRxiv : the preprint server for biology · 2026Article
- Reproducible clinical archetypes in acute respiratory failure: a multi-cohort trajectory analysis.Intensive care medicine · 2026Article
- DNA methylation profiles at hospital admission are associated with subsequent severe COVID-19 outcomes.Clinical epigenetics · 2026Article
- A quantitative metabolic signature of host response during SARS-CoV-2 infection and recovery.iScience · 2026Article
- Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19.Nature microbiology · 2026Article
- Real-world immune dynamics following COVID-19 vaccination and breakthrough infection: a paired-sample study in Zhejiang Province, China.Frontiers in immunology · 2026Article
- Immune-endothelial-coagulation crosstalk as a driver of multi-organ dysfunction in severe viral pneumonia.Frontiers in immunology · 2026Review
- MTHFR allele and one-carbon metabolic profile predict severity of COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Minimalistic transcriptomic signatures permit accurate early prediction of COVID-19 mortality.JCI insight · 2025Article
- A multiomics recovery factor predicts long COVID in the IMPACC study.The Journal of clinical investigation · 2025Article
- Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort.The journal of allergy and clinical immunology. Global · 2025Article
- Algorithms for appropriate patient stratification in the face of a new SARS-CoV-2 pandemic.Immunity & ageing : I & A · 2025Article
- Single-Cell RNA-Seq Identifies Immune Remodeling in Lungs of β-Carotene Oxygenase 2 Knockout Mice with Improved Antiviral Response.Nutrients · 2025Article
- Circulating endothelial signatures correlate with worse outcomes in COVID-19, respiratory failure and ARDS.Critical care (London, England) · 2025Article
- Longitudinal Meta-cohort study protocol using systems biology to identify vaccine safety biomarkers.Vaccine · 2025Article
- MICBG406A polymorphism reduces risk of mechanical ventilation and death during viral acute lung injury.JCI insight · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors at 12 institutions in 1 country.
Joann Diray-ArceClinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: joann.arce@childrens.harvard.edu.
Slim FouratiEmory School of Medicine, Atlanta, GA 30322, USA.
Naresh Doni JayaveluBenaroya Research Institute, University of Washington, Seattle, WA 98101, USA.
Ravi PatelUniversity of California San Francisco, San Francisco, CA 94115, USA.
Cole MaguireThe University of Texas at Austin, Austin, TX 78712, USA.
Ana C ChangClinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA.
Ravi DandekarUniversity of California San Francisco, San Francisco, CA 94115, USA.
Jingjing QiIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Brian H LeeIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Patrick van ZalmPrecision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Andrew SchroederUniversity of California San Francisco, San Francisco, CA 94115, USA.
Ernie ChenYale School of Medicine, New Haven, CT 06510, USA.
Anna KonstorumYale School of Medicine, New Haven, CT 06510, USA.
Anderson BritoYale School of Public Health, New Haven, CT 06510, USA.
Jeremy P GygiYale School of Medicine, New Haven, CT 06510, USA.
Alvin KhoClinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA.
Jing ChenClinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Shrikant PawarYale School of Medicine, New Haven, CT 06510, USA.
Ana Silvia Gonzalez-ReicheIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Annmarie HochClinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Carly E MillirenClinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA.
James A OvertonKnocean, Inc., Toronto, ON M6P 2T3, Canada.
Kerstin WestendorfLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
IMPACC Network
Charles B CairnsDrexel University, Tower Health Hospital, Philadelphia, PA 19104, USA.
Nadine RouphaelEmory School of Medicine, Atlanta, GA 30322, USA.
Steven E BosingerEmory School of Medicine, Atlanta, GA 30322, USA.
Seunghee Kim-SchulzeIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Florian KrammerIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Lindsey RosenNational Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20814, USA.
Nathan D GrubaughYale School of Public Health, New Haven, CT 06510, USA.
Harm van BakelIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Michael WilsonUniversity of California San Francisco, San Francisco, CA 94115, USA.
Jayant RajanUniversity of California San Francisco, San Francisco, CA 94115, USA.
Hanno SteenPrecision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Walter EckalbarUniversity of California San Francisco, San Francisco, CA 94115, USA.
Chris CotsapasYale School of Medicine, New Haven, CT 06510, USA; Broad Institute of MIT & Harvard, Cambridge, MA 02142, USA.
Charles R LangelierUniversity of California San Francisco, San Francisco, CA 94115, USA.
Ofer LevyPrecision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT & Harvard, Cambridge, MA 02142, USA.
Matthew C AltmanBenaroya Research Institute, University of Washington, Seattle, WA 98101, USA.
Holden MaeckerStanford University School of Medicine, Palo Alto, CA 94305, USA.
Ruth R MontgomeryYale School of Medicine, New Haven, CT 06510, USA.
Elias K HaddadDrexel University, Tower Health Hospital, Philadelphia, PA 19104, USA.
Rafick P SekalyEmory School of Medicine, Atlanta, GA 30322, USA.
Denise EssermanYale School of Public Health, New Haven, CT 06510, USA.
Al OzonoffClinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT & Harvard, Cambridge, MA 02142, USA.
Patrice M BeckerNational Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20814, USA.
Alison D AugustineNational Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20814, USA.
Leying GuanYale School of Public Health, New Haven, CT 06510, USA.
Bjoern PetersLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Steven H KleinsteinYale School of Medicine, New Haven, CT 06510, USA. Electronic address: steven.kleinstein@yale.edu.
Yale University · USIcahn School of Medicine at Mount Sinai · USUniversity of California, San Francisco · USBoston Children's Hospital · USNational Institute of Allergy and Infectious Diseases · USEmory University · USBroad Institute · USUniversity of Washington · USDrexel University · USLa Jolla Institute for Immunology · USPalo Alto University · USThe University of Texas at Austin · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MUsing a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MTranslation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK · 2004 to 2023
$56.2MSystems investigation of vaccine responses in B cell depleted autoimmune patientsU19AI089992 · NIAID · YALE UNIVERSITY · PI Albert C Shaw · 2010 to 2026
$50.4MProject 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HARRIS, EVA · 2015 to 2021
$46.6MConduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4MSystems Biological Analysis of Innate and Adaptive Responses to VaccinationU19AI090023 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, LI, SHUZHAO · 2010 to 2021
$45.0MUnderstanding Asthma EndotypesU19AI077439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2008 to 2026
$41.1MTranscriptomics to define biomarkers of neonatal vaccine immunogenicityU19AI118608 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2017 to 2021
$24.7MTollip inhibits IL-33 signaling during airway influenza virus infectionU19AI125357 · NIAID · UNIVERSITY OF ARIZONA · PI KRAFT, MONICA, VERCELLI, DONATA · 2016 to 2025
$14.7MSystems biological assessment of T cell responses to vaccinationU19AI167903 · NIAID · STANFORD UNIVERSITY · PI BALI PULENDRAN · 2022 to 2026
$13.2MProject 3: Mapping the Evolution of Chronic Transplant Injury in the Context of CMV InfectionU19AI128913 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F, SARWAL, MINNIE M · 2017 to 2021
$11.2MNCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR004419NIAID NIH HHS R01 AI104870NIAID NIH HHS R01 AI122220NIAID NIH HHS R01 AI132774NIAID NIH HHS R01 AI135803NIAID NIH HHS R01 AI145835NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI062629NIAID NIH HHS U19 AI077439NIAID NIH HHS U19 AI089992NIAID NIH HHS U19 AI090023NIAID NIH HHS U19 AI118608NIAID NIH HHS U19 AI118610NIAID NIH HHS U19 AI125357NIAID NIH HHS U19 AI128910NIAID NIH HHS U19 AI128913NIAID NIH HHS U19 AI167903NIAID NIH HHS U54 AI142766NIA NIH HHS K24 AG042489NICHD NIH HHS T32 HD007149NIH HHS S10 OD026880NIH HHS S10 OD030463
Abstract
The IMPACC cohort, composed of >1,000 hospitalized COVID-19 participants, contains five illness trajectory groups (TGs) during acute infection (first 28 days), ranging from milder (TG1-3) to more severe disease course (TG4) and death (TG5). Here, we report deep immunophenotyping, profiling of >15,000 longitudinal blood and nasal samples from 540 participants of the IMPACC cohort, using 14 distinct assays. These unbiased analyses identify cellular and molecular signatures present within 72 h of hospital admission that distinguish moderate from severe and fatal COVID-19 disease. Importantly, cellular and molecular states also distinguish participants with more severe disease that recover or stabilize within 28 days from those that progress to fatal outcomes (TG4 vs. TG5). Furthermore, our longitudinal design reveals that these biologic states display distinct temporal patterns associated with clinical outcomes. Characterizing host immune responses in relation to heterogeneity in disease course may inform clinical prognosis and opportunities for intervention.
Indexed as
COVID-19Disease ProgressionHumansLongitudinal StudiesMultiomicsSARS-CoV-2COVID-19immunophenotypinglongitudinal modelingmulti-omicsSARS-CoV-2systems immunology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.